Trial Profile

Phase I/IIa Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary)
Indications Advanced breast cancer; Anal cancer; Bladder cancer; Bone cancer; Colorectal cancer; Gastric cancer; Gynaecological cancer; Head and neck cancer; Liver cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Salivary gland cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Cerulean Pharma; NewLink Genetics Corporation

Most Recent Events

16 Feb 2021 Results published in the Investigational New Drugs
21 Dec 2017 Status changed from active, no longer recruiting to discontinued.
23 Feb 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com